CSS
CLDX icon

Cubist Systematic Strategies’s Celldex Therapeutics CLDX Stock Holding History

Cubist Systematic Strategies’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$788K Buy
+30,446
New +$705K ﹤0.01% 2059
2025
Q1 		– Sell
-154,512
Closed -$3.9M – 2931
2024
Q4 		$3.9M Buy
+154,512
New +$4.2M 0.02% 978
2024
Q2 		– Sell
-67,434
Closed -$2.83M – 3122
2024
Q1 		$2.83M Buy
+67,434
New +$2.77M 0.02% 1370
2023
Q3 		– Sell
-11,460
Closed -$389K – 3410
2023
Q2 		$389K Buy
11,460
+8,678
+312% +$292K ﹤0.01% 2522
2023
Q1 		$100K Buy
2,782
+1,226
+79% +$52.9K ﹤0.01% 3437
2022
Q4 		$69.4K Buy
1,556
+1,547
+17,189% +$55.2K ﹤0.01% 3858
2022
Q3 		$0 Buy
+9
New +$276 ﹤0.01% 4449
2022
Q2 		– Sell
-12,633
Closed -$430K – 4378
2022
Q1 		$430K Sell
12,633
-16,353
-56% -$523K ﹤0.01% 2625
2021
Q4 		$1.12M Buy
28,986
+7,063
+32% +$308K 0.01% 1835
2021
Q3 		$1.18M Sell
21,923
-972
-4% -$45.6K 0.01% 1389
2021
Q2 		$766K Sell
22,895
-2,206
-9% -$60.6K 0.01% 1739
2021
Q1 		$517K Buy
+25,101
New +$576K 0.01% 1936
2018
Q2 		– Sell
-6,134
Closed -$214K – 1820
2018
Q1 		$214K Buy
6,134
+3,141
+105% +$122K 0.01% 1358
2017
Q4 		$128K Buy
2,993
+641
+27% +$27.5K 0.01% 1648
2017
Q3 		$101K Buy
+2,352
New +$88.2K 0.01% 1626
2017
Q1 		– Sell
-854
Closed -$45K – 1655
2016
Q4 		$45K Sell
854
-921
-52% -$52.4K ﹤0.01% 1591
2016
Q3 		$108K Buy
1,775
+398
+29% +$24.8K 0.01% 1446
2016
Q2 		$91K Buy
+1,377
New +$87.4K 0.01% 1523
2016
Q1 		– Sell
-726
Closed -$171K – 1632
2015
Q4 		$171K Sell
726
-2,042
-74% -$445K 0.01% 1403
2015
Q3 		$438K Buy
2,768
+2,141
+341% +$606K 0.02% 1035
2015
Q2 		$237K Sell
627
-902
-59% -$358K 0.01% 1351
2015
Q1 		$639K Buy
+1,529
New +$547K 0.03% 792
2014
Q3 		– Sell
-1,009
Closed -$247K – 1746
2014
Q2 		$247K Buy
+1,009
New +$228K 0.01% 1050

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cubist Systematic Strategies's CLDX Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Celldex Therapeutics (CLDX) in Q3 2025: 30,446 shares worth $788K. The stake represents ﹤0.01% of the portfolio and ranks #2059 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in CLDX as recently as Q4 2024.

Cubist Systematic Strategies first reported a position in CLDX in Q2 2014 and has held it in 23 quarters since. The position peaked at $3.9M in Q4 2024. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • Cubist Systematic Strategies held 30,446 shares of Celldex Therapeutics worth $788K as of Q3 2025.
  • Celldex Therapeutics was a new Cubist Systematic Strategies position in Q3 2025.
  • Celldex Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2059 holding.
  • Cubist Systematic Strategies first reported a position in Celldex Therapeutics in Q2 2014 and has held it in 23 quarters since.
  • Cubist Systematic Strategies's Celldex Therapeutics position peaked at $3.9M in Q4 2024.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.